Bristol-Myers Squibb Company

BMY

US1101221083

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

2024-07-26 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

44.04 USD

Average target price

53.19 USD

Spread / Average Target

+20.79%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-14.66%	89.27B
ELI LILLY AND COMPANY	+33.37%	700B
JOHNSON & JOHNSON	-4.89%	358B
MERCK & CO., INC.	+18.86%	330B
ABBVIE INC.	+3.37%	287B
ASTRAZENECA PLC	+15.70%	236B
NOVARTIS AG	+6.68%	202B
ROCHE HOLDING AG	-9.08%	197B
AMGEN INC.	+5.67%	161B
PFIZER, INC.	-2.19%	157B

Other Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 14:20:10 2024-05-08 EDT			5-day change	1st Jan Change
43.78 ^USD	-0.60%		-0.95%	-14.66%

05-07	Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	MT
05-06	Top Midday Stories: Tyson Shares Tumble on Earnings Miss; Robinhood Receives Wells Notice From SEC Staff; Spirit Airlines to Furlough up to 260 Pilots; Shell in Talks to Sell Malaysian Gas Station Business to Saudi Aramco	MT

Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	05-07	MT
Top Midday Stories: Tyson Shares Tumble on Earnings Miss; Robinhood Receives Wells Notice From SEC Staff; Spirit Airlines to Furlough up to 260 Pilots; Shell in Talks to Sell Malaysian Gas Station Business to Saudi Aramco	05-06	MT
Bristol-Myers Squibb Says Applications for Opdivo Accepted by US, European Regulators	05-06	MT
Bristol-Myers Gets FDA Acceptance of Review for Subcutaneous Opdivo Formulation	05-06	DJ
Bristol-Myers: BLA accepted for subcutaneous Opdivo	05-06	CF
U.S. Food and Drug Administration Accepts Bristol Myers Squibb?s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)	05-06	CI
European Medicines Agency Validates Bristol Myers Squibb?s Application for Opdivo Plus Yervoy for the First-Line Treatment of Adult Patients with Microsatellite Instability?High or Mismatch Repair Deficient Metastatic Colorectal Cancer	05-06	CI
HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50	05-01	MT
Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration	05-01	MT
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration	05-01	CI
Global markets live: Adidas, Mercedes, McDonalds, Eli Lilly, PayPal, MicroStrategy, Tesla...	04-30
A flurry of corporate results ahead of the Fed's rate decision	04-30
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American...	04-30
Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb	04-30	CI
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	04-30	RE
J&J, Bristol Myers lose challenges to US drug price negotiation program	04-29	RE
Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60	04-29	MT
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating	04-29	MT
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases	04-29	CI
S&P 500 Q1 earnings estimated growth improves; stocks up for week	04-26	RE
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51	04-26	MT
UBS Cuts Bristol-Myers Squibb Price Target to $47 From $52, Maintains Neutral Rating	04-26	MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $51	04-26	MT
JPMorgan Adjusts Bristol-Myers Squibb's Price Target to $60 From $65	04-26	MT
Bristol-Myers Squibb Says European Regulator Recommends Approval of Bladder Cancer Combination Therapy	04-26	MT